MetALD: AGA Defines How to Manage the “Metabolic + Alcohol” Overlap: CGH | September 2026

What Does the AGA Recommend?

The new AGA Clinical Practice Update provides 9 Best Practice Advice statements for MetALD—the increasingly recognised overlap between metabolic dysfunction and clinically relevant alcohol exposure.

• MetALD corresponds to alcohol intake of approximately 140–350 g/week in women and 210–420 g/week in men, alongside cardiometabolic risk.
• Assess alcohol consumption at diagnosis and at least annually, using history, AUDIT-C and, when appropriate, biomarkers such as PEth or urinary EtG.
• Alcohol and metabolic dysfunction act synergistically; patients should be advised toward abstinence, particularly when fibrosis is present.
• Stage fibrosis sequentially with FIB-4 → VCTE/ELF, reserving biopsy for selected discordant cases.
• Interpret liver stiffness cautiously during active drinking; inflammation can transiently elevate LSM. Reassessment after 2–4 weeks of alcohol reduction/abstinence may be appropriate.
• Management must simultaneously address weight, exercise, cardiometabolic disease, nutrition and micronutrient deficiencies.
• Resmetirom and semaglutide have not been formally established for MetALD; emerging GLP-1/GIP data on alcohol craving are promising but preliminary.
• Moderate/severe AUD should be actively treated with pharmacotherapy plus behavioural interventions.
• Bariatric/endobariatric procedures are not currently advised in active MetALD because of limited evidence and concern about post-procedure alcohol-related harm.

GastroAGI Takeaway

MetALD should not be managed as “MASLD plus a little alcohol.” The AGA treats alcohol exposure as a dynamic, modifiable disease driver that should be measured repeatedly and treated alongside metabolic dysfunction and fibrosis risk. The practical model is: quantify alcohol → stage fibrosis → treat AUD + metabolic risk together → reassess longitudinally.